Health Care • Biotechnology: Pharmaceutical Preparations
$0.44 ▼ -0.01
(-3.16%)
MKT CAP: $8.5M • VOL: 177.5K
52W L $0 52W H $2
ROARABLE / RQD
D- • 35/100
PIOTROSKI
2 / 9
ENSC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $5.1M | $5.2M | $2.2M |
| YoY Revenue Growth % | -2.8% | +133.6% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$10.2M | -$6.7M | -$10.7M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$10.2M | -$8.0M | -$10.6M |
| EBITDA (Normalized) | -$10.1M | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$7.8M | -$7.5M | -$10.8M |
| Capital Expenditures (CapEx) | $123.6K | — | — |
| Free Cash Flow (FCF) | -$7.9M | -$7.5M | -$10.8M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $4.3M | $3.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $3.2M | $3.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ENSC.